Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Consensus Target Price from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $22.25.

A number of brokerages have recently issued reports on ACRS. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Monday, August 19th. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard acquired 235,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was acquired at an average cost of $1.15 per share, with a total value of $270,250.00. Following the acquisition, the insider now directly owns 11,787,134 shares of the company’s stock, valued at approximately $13,555,204.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have purchased 1,080,502 shares of company stock worth $1,288,732. 6.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors have recently bought and sold shares of the stock. Trium Capital LLP acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $2,081,000. Russell Investments Group Ltd. raised its position in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 61,602 shares during the period. Octagon Capital Advisors LP bought a new position in Aclaris Therapeutics in the 4th quarter worth $105,000. BNP Paribas Financial Markets lifted its position in shares of Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock worth $6,113,000 after buying an additional 207,418 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $1.17 on Tuesday. Aclaris Therapeutics has a 1-year low of $0.59 and a 1-year high of $8.28. The company has a 50-day moving average of $1.24 and a two-hundred day moving average of $1.21. The firm has a market cap of $83.38 million, a PE ratio of -1.07 and a beta of 0.21.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. The company had revenue of $2.77 million for the quarter, compared to analyst estimates of $1.74 million. Sell-side analysts anticipate that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.